Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06947382 · ClinicalTrials.gov registry record

Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

A clinical trial of PDAC - Pancreatic Ductal Adenocarcinoma and Cancer Diagnosis, sponsored by Immunovia.

Completed
Registry status
1,066
Enrollment target
15
Study locations

NCT06947382 is a study of PDAC - Pancreatic Ductal Adenocarcinoma and Cancer Diagnosis that has completed, run by Immunovia. The registered enrollment target is 1,066 participants, below the 1,238-participant average among 10 other PDAC - Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (14% lower). The trial reports 15 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06947382, a study of PDAC - Pancreatic Ductal Adenocarcinoma and Cancer Diagnosis, has completed, sponsored by Immunovia.

COMPLETED
Registry status
1,066 participants
Enrollment target
15
Study locations

Study Summary

This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to familial/genetic history or clinical symptoms.

Conditions Studied

PDAC - Pancreatic Ductal Adenocarcinoma Cancer Diagnosis Pancreatic Cancer Stage I Pancreatic Cancer Stage II

Study Locations (15)

California

  • St. John's Cancer Institute - Burbank
  • University of California San Diego - La Jolla
  • Stanford Gastroenterology and Hepatology - Stanford

Other

  • The Research Institute of the McGill University Health Centre - Montreal
  • University of Verona - Verona
  • Oslo University Hospital - Oslo

Virginia

  • Inova Schar Cancer Institute - Fairfax
  • Virginia Commonwealth University - Richmond

Arizona

  • HonorHealth Clinical Research Institute - Scottsdale

Florida

  • University of Miami - Miami

Illinois

  • University of Chicago Medical Center - Chicago

New York

  • Mount Sinai Hospital - New York

Oregon

  • Oregon Health Sciences University - Portland

Trial Details

FieldValue
Enrollment Target 1,066 participants
Start Date 2024-09-02
Est. Completion 2025-01-06

Sponsor

Immunovia

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06947382

The ClinicalTrials.gov registry entry for NCT06947382 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,066 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,238-participant average among 10 other PDAC - Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (14% lower). The listed sponsor is Immunovia, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with PDAC - Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.

NCT06947382 reports 15 study locations spanning 10 distinct geographic areas - top geographies include California, Other, Virginia.

Frequently Asked Questions

What is clinical trial NCT06947382 about?

NCT06947382 is a clinical study titled "Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer". This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to fa...

What is the current status of trial NCT06947382?

This trial is currently completed. The enrollment target is 1,066 participants. The study started on 2024-09-02. Estimated completion is 2025-01-06.

What conditions does trial NCT06947382 study?

This clinical trial studies the following conditions: PDAC - Pancreatic Ductal Adenocarcinoma, Cancer Diagnosis, Pancreatic Cancer Stage I, Pancreatic Cancer Stage II.

Who is sponsoring clinical trial NCT06947382?

This trial is sponsored by Immunovia, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06947382 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for PDAC - Pancreatic Ductal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

PDAC - Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Cancer Diagnosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.